Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
8 citing papers in PubMed, 8 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
42 authors at 5 institutions in 1 country.
Jingyou YuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0002-0775-6623
Paul V ThomasEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.ORCID 0000-0002-6772-3997
Katherine McMahanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0002-3933-0539
Catherine Jacob-DolanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0001-6641-0342
Jinyan LiuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0003-0504-2181
Xuan HeCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0002-9448-4426
David HopeCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0001-5654-1744
Elizabeth J MartinezEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.ORCID 0000-0002-7755-7056
Wei-Hung ChenEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
Michaela SciaccaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Nicole P HachmannCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0002-2100-8461
Michelle LiftonCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0003-0279-2198
Jessica MillerCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0002-0641-762X
Olivia C PowersCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Kevin HallCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Cindy WuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0001-6924-5346
Julia BarrettCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0002-5857-3632
Isabella SwaffordEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.ORCID 0000-0001-8638-2772
Jeffrey R CurrierEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.ORCID 0000-0002-5696-0268
Jocelyn KingViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.ORCID 0000-0003-3348-1632
Courtney CorbittEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
William C ChangEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.ORCID 0000-0003-4967-6426
Emily GolubEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.ORCID 0000-0003-4165-2382
Phyllis A ReesEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.ORCID 0000-0001-9755-8403
Caroline E PetersonEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.ORCID 0000-0002-6087-7301
Agnes HajduczkiEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
Elizabeth HussinHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Camille LangeHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.ORCID 0000-0003-2666-7850
Hua GongHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Gary R MatyasU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.ORCID 0000-0002-2074-2373
Mangala RaoU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.ORCID 0000-0001-9553-4969
Dominic Paquin-ProulxEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.ORCID 0000-0003-1407-3414
Gregory D GromowskiViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.ORCID 0000-0003-4576-4277
Meredith Davis-GardnerEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA.ORCID 0000-0002-6133-3613
Mehul S SutharEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA.ORCID 0000-0002-2686-8380
Nelson L MichaelCenter for Infectious Diseases Research, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.ORCID 0000-0001-5882-5548
Diane L BoltonEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.ORCID 0000-0003-1897-499X
M Gordon JoyceEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.ORCID 0000-0002-6808-7232
Kayvon ModjarradEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.ORCID 0000-0002-6514-5572
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0001-5127-4659
Henry M. Jackson Foundation · USBeth Israel Deaconess Medical Center · USWalter Reed Army Institute of Research · USBioqual · USEmory University · US
Funding
Immunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7M
NCI NIH HHS U01 CA260476
6 · The paper itself
Abstract
Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and waning immunity call for next-generation vaccine strategies. Here, we assessed the immunogenicity and protective efficacy of two SARS-CoV-2 vaccines targeting the WA1/2020 spike protein, Ad26.COV2.S (Ad26) and Spike ferritin Nanoparticle (SpFN), in nonhuman primates, delivered as either a homologous (SpFN/SpFN and Ad26/Ad26) or heterologous (Ad26/SpFN) prime-boost regimen. The Ad26/SpFN regimen elicited the highest CD4 T cell and memory B cell responses, the SpFN/SpFN regimen generated the highest binding and neutralizing antibody responses, and the Ad26/Ad26 regimen generated the most robust CD8 T cell responses. Despite these differences, protective efficacy against SARS-CoV-2 Omicron BA.1 challenge was similar for all three regimens. After challenge, all vaccinated monkeys showed significantly reduced peak and day 4 viral loads in both bronchoalveolar lavage and nasal swabs as compared with sham animals. The efficacy conferred by these three immunologically distinct vaccine regimens suggests that both humoral and cellular immunity contribute to protection against SARS-CoV-2 Omicron challenge.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN. · full record | OpenQuestion